Group 1 - Univest Securities, LLC announced the closing of a registered direct offering for PMGC Holdings Inc., raising approximately $1.48 million through the sale of 294,450 shares at a price of $5.04 per share [1][2][3] - The offering was conducted under a shelf registration statement previously filed and declared effective by the SEC on February 7, 2025 [4] - PMGC Holdings Inc. is a diversified holding company with a portfolio that includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [7]

Core Viewpoint - PMGC Holdings Inc. has entered into a definitive agreement for a registered direct offering of 294,450 shares at a price of $5.04 per share, expected to raise approximately $1.48 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the sale of common stock or pre-funded warrants, with the purchase price for the pre-funded warrants being the same as the shares, minus an exercise price of $0.001 per share [1]. - The transaction is anticipated to close on or about March 24, 2025, pending customary closing conditions [2]. - The company will have approximately 872,411 shares of common stock issued and outstanding following the offering [1]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, which was declared effective by the SEC on February 7, 2025 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the offering [3]. Group 3: Company Overview - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [5]. - The company's portfolio includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [5].

Group 1 - PMGC Holdings Inc. has repurchased shares from certain existing shareholders who contacted the company directly, with details available in the Company's Form 8-K filings [1] - The company is open to considering additional share repurchases from other investors, depending on market conditions and other factors [1] - Shareholders interested in discussing potential repurchases are encouraged to contact the company directly in writing [2] Group 2 - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [4] - The company's portfolio currently consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [4] - The company is committed to exploring opportunities in multiple sectors to maximize growth and value [4]

Core Insights - Northstrive Biosciences Inc. has scheduled a pre-Investigational New Drug (pre-IND) meeting with the FDA on April 23, 2025, to discuss the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation [1][3][7] - EL-22 is a novel engineered probiotic designed to express myostatin on its surface, targeting the myostatin pathway to support muscle health, with preclinical studies showing significant improvements in models of Duchenne muscular dystrophy [2][4] - The company aims to file the IND application in 2025 and initiate clinical trials to evaluate the combination of EL-22 with GLP-1 receptor agonists for obesity treatment [3][4] Company Overview - Northstrive Biosciences Inc. is a subsidiary of PMGC Holdings Inc., focusing on the development of innovative aesthetic medicines, with EL-22 being its lead asset [4][5] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries [5]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3][4] Purpose of the Reverse Stock Split - The reverse stock split is essential for maintaining compliance with Nasdaq's listing requirements, which will enhance visibility and investor confidence, positioning the company for future growth [3] - There is no guarantee that the company will meet the minimum bid price requirement after the split [3] Nasdaq Rule Changes and Compliance Considerations - The reverse stock split is in response to recent Nasdaq rule changes aimed at ensuring compliance with listing requirements, particularly maintaining a stable share price above the minimum threshold [4] - The amendments highlight the company's commitment to addressing potential noncompliance issues proactively [4] Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7] - Fractional shares will be rounded up to one full share for each fractional portion [7] - The trading symbol will remain "ELAB," but a new CUSIP number will be assigned [7] - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7] Post-Split Share Structure - Post-split, approximately 577,000 shares of common stock will be issued and outstanding as of March 10, 2025 [9] - The total number of authorized shares will also decrease at the same 1-for-7 ratio as the issued and outstanding shares [9]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3]. Group 1: Purpose and Compliance - The reverse stock split is essential for PMGC to meet Nasdaq's listing requirements, thereby maintaining its visibility and investor confidence [3]. - Recent Nasdaq rule changes necessitate this action to ensure compliance, particularly regarding maintaining a stable share price above the minimum threshold [4]. Group 2: Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7]. - Fractional shares will be rounded up to one full share, and the trading symbol will remain "ELAB" with a new CUSIP number assigned [7]. - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7]. Group 3: Post-Split Structure - After the split, approximately 577,000 shares of common stock will be issued and outstanding [9]. - The total number of authorized shares will also decrease at the same 1-for-7 ratio, eliminating the need for shareholder approval [9].

Core Insights - PMGC Holdings Inc. has announced its annual sponsorship of TCA Venture Group's Orange County network for 2025, aiming to enhance its investment and M&A opportunities while supporting local business growth [1][5] - TCA Venture Group is recognized as one of the largest and most active angel investor networks in the U.S., having invested over $300 million in more than 525 companies since its inception in 1997 [2][4] - The collaboration with TCA is expected to provide PMGC with access to a vast network of over 400 seasoned investors and industry professionals, enhancing its acquisition strategy and portfolio expansion [4][5] Company Overview - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries, currently comprising three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [6] - Northstrive Biosciences Inc. focuses on developing aesthetic medicines, particularly addressing obesity through innovative probiotic approaches [7] - PMGC Research Inc. is engaged in R&D, leveraging Canadian research grants to accelerate scientific discovery [7] - PMGC Capital LLC operates as a multi-strategy investment firm, targeting undervalued companies and assets for sustainable growth [7] TCA Venture Group Overview - TCA Venture Group, formerly known as Tech Coast Angels, has a history of over 25 years in funding early-stage companies across innovation-driven industries, having attracted an additional $2.2 billion in follow-on investments from venture capital firms [2][4] - TCA members provide not only capital but also mentorship, board representation, and strategic partnerships, contributing significantly to the entrepreneurial ecosystem in Southern California [4][8] - TCA has been ranked as the 2 U.S. angel investment network for funded deals and recognized for its network centrality by CB Insights [4]

Core Viewpoint - PMGC Holdings Inc. has announced an update on its capital structure, emphasizing its strong financial position and commitment to strategic priorities through its subsidiaries [1][2]. Capital Structure and Financial Position - As of February 25, 2025, PMGC's capital structure includes 4,042,295 common shares outstanding, 4,931 stock options with a weighted-average exercise price of $304 per share, and 979,814 warrants with a weighted-average exercise price of $4.91 per share [5]. - The company has zero debt, indicating a strong balance sheet [5]. - Recent capital raises include $8.0 million from an S-1 offering in September 2024 and approximately $1.9 million from a warrant inducement offering in January 2025 [5]. Subsidiaries and Business Focus - PMGC Holdings operates through three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. - Northstrive Biosciences focuses on developing aesthetic medicines, particularly targeting obesity treatment with its lead asset, EL-22 [5]. - PMGC Research is dedicated to R&D, leveraging Canadian research grants and partnerships with universities to commercialize technologies [5]. - PMGC Capital is a multi-strategy investment firm that seeks undervalued companies and assets to drive sustainable growth [5].

NorthStrive Biosciences Overview - NorthStrive Biosciences, a division of PMGC Holdings, is focused on developing therapeutics for obesity and aesthetics[6] - The company licensed EL-22, a first-in-class asset designed to preserve muscle during GLP-1 obesity treatments[6] - NorthStrive is actively seeking additional pipeline assets and recruiting experienced team members[6] Obesity Market and Unmet Needs - Nearly half of Americans are projected to suffer from obesity by 2030[7] - Past GLP-1 studies indicate approximately 40% of weight loss is due to loss of lean muscle[9] - Physicians are concerned about patients losing muscle during GLP-1 treatment and regaining fat afterward[9] EL-22 and EL-32 Development - EL-22 is an engineered probiotic expressing modified human myostatin[17, 20, 29] - Preclinical data shows EL-22 inhibits weight loss caused by muscle loss in DMD mice models, improving exercise capacity and muscle strength[31] - In preclinical studies, body weight in EL-22 group increased 10.67g vs 8.29g in control group (p=0.01)[33] - EL-22 Phase 1 clinical trial (n=37) completed in South Korea showed good safety and tolerability profiles up to 2,000 mg/day[35, 43] - EL-32 is an engineered probiotic expressing both Myostatin & Activin-A antigens[19, 44, 46] - Preclinical data for EL-32 in healthy mice showed statistically significant Activin A (p=0.0034) and myostatin (p=0.0047) antibody production[47, 48] Competitive Advantages - NorthStrive Biosciences believes its assets would be the only oral Myostatin formulations to date and be early movers in the emerging GLP-1 combination space[55] - The Myostatin pathway has been validated by the likes of Eli Lilly's $1.9 billion acquisition of Versanis[54]

Core Viewpoint - Northstrive Biosciences Inc. is advancing its obesity treatment candidates, EL-22 and EL-32, focusing on fat loss while preserving muscle mass, with plans for regulatory meetings and clinical trials in 2025 [1][4][6]. Group 1: EL-22 Development - Northstrive is preparing for a Type B pre-IND meeting with the FDA in Q2 2025, having completed necessary translations and compiled data from its South Korean partner [2][3]. - EL-22 is a novel engineered probiotic targeting the myostatin pathway, showing significant improvements in preclinical studies and safety in a Phase 1 trial in South Korea [3][4]. - The company aims to file an Investigational New Drug application in 2025 to initiate clinical trials combining EL-22 with GLP-1 receptor agonists for obesity treatment [4][8]. Group 2: EL-32 Development - Northstrive has engaged a leading CRO for a preclinical study of EL-32, which expresses dual myostatin and activin-A inhibitors, focusing on glycemic control and body composition in diet-induced obese mice [5][8]. - The study will evaluate EL-32 both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide [5]. Group 3: Upcoming Presentation - Northstrive will present its obesity drug candidates at the UCLA Obesity Symposium on February 7, 2025, highlighting the muscle-preserving therapeutic potential of its myostatin-engineered probiotics [6]. Group 4: Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on innovative treatments for obesity while preserving muscle mass during weight loss therapies [7][8].